TargetBeta
NCBP2
nuclear cap binding protein subunit 2 · also NIP1, CBP20, Cbc2 · RNA binding motif containing
1 program in company-led studies act on NCBP2, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| obefazimodrule | Abivax | – | phase 3 | 214 running | NCBP1 | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Arthritis, Rheumatoid, 1 program
- Colitis, Ulcerative, 1 program
- COVID-19, 1 program
- Crohn Disease, 1 program
- HIV Infections, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026obefazimod · Abivax · phase 3 · NCT06456593
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.